Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04111978
Other study ID # ENGOT-ov54/Swiss-GO-2/MATAO
Secondary ID 2019-002264-27EN
Status Recruiting
Phase Phase 3
First received
Last updated
Start date November 5, 2020
Est. completion date October 1, 2030

Study information

Verified date June 2023
Source Swiss GO Trial Group
Contact Pamela McLaughlin, PhD
Phone +41 61 328 42 04
Email pamela.mclaughlin@usb.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo. The study's primary hypothesis is that the treatment with letrozole increases progression free survival in comparison to the maintenance standard treatment (superiority trial).


Description:

Femara (letrozole) is an extensively investigated, marketed aromatase inhibitor (AI) widely used as treatment in the maintenance phase of estrogen-receptor (ER) positive breast cancer, as it inhibit the synthesis of estrogens. Estrogen is a well known driver of cancer growth in ER-positive tumors and a high percentage of the epithelial ovarian cancers express ER as well. Of which low grade ovarian cancers demonstrates the highest level of expression, supporting our strategy of a sub-group analysis (LOGOS). Therefore, letrozole in this study be investigated prospectively and evaluated as maintenance therapy after standard surgical and chemotherapy treatment in comparison to placebo (which is the current standard maintenance treatment) in subjects with primary, ER-positive low or high grade serous or endometrioid epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) of FIGO Stage II-IV, whose cancer has not progressed by the end of the platinum-based chemotherapy. The objectives are to evaluate the letrozole maintenance treatment compared to placebo in terms of - progression-free survival (PFS; primary endpoint) - overall survival (OS) - quality-adjusted progression free survival (QAPFS) - time to first subsequent treatment (TFST) - quality-adjusted time without symptoms of toxicity (Q-TWiST) - health related quality of life (QoL) assessed by EQ-5D-5L, FACT-ES and FACT-O questionnaires Methods: 540 for this study eligible subjects are 1:1 allocated in this randomized, controlled, double-blinded, multi-centre study to either the test (letrozole) or control (placebo) group. The maximum maintenance treatment duration is 5 years or until symptoms of toxicity or progression of underlying disease. Health and health-related quality of life will continuously be assessed at study entry and during routine recalls which are scheduled every 12 weeks for the first 2 years, followed by every 24 weeks for the next 3 years. Procedures performed to assess the participants' health are the same as are performed during the regular routine ovarian cancer follow-up visits: blood tests, physical as well as gynaecological examinations and may include imaging. In addition, the participants are asked to complete during the study quality of life (QoL) specific questionnaires and wear an activity tracker for one week just before the scheduled visits. These assessments will be used for the evaluation of letrozole's efficacy and burden in comparison to the standard maintenance treatment. Survival follow-up data after the mainentance treatment duration of 5 years (study end) are obtained for up to another 7 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 540
Est. completion date October 1, 2030
Est. primary completion date October 1, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients must be = 18 years of age - Willing and able to attend the visits and to understand all study-related procedures. - Primary, newly diagnosed FIGO Stage II to IV and histologically confirmed low or high grade serous or endometrioid epithelial ovarian/fallopian tube/peritoneal cancer - (Interval-) debulking performed ECOG-Performance Status 0-2 - Signed informed consents (ICF-1; ICF-2) - Paraffin-embedded tissue or paraffin-embedded cell block (from ascites) available - Positivity (= 1%) for ER expression (only determined by Histopathology Core Facility of MATAO trial) - At least 4 cycles of platinum-based chemotherapy (neoadjuvant allowed) - Negative serum pregnancy test in women of childbearing potential who will get/have gotten a surgical resection or radiation sterilization, prior to the intervention in the therapeutical maintenance setting. Exclusion Criteria: - Progressive disease at the end of adjuvant treatment as defined in chapter 9.2.1 of protocol - Women of childbearing potential (not having undergone a surgical or radiation sterilization and not getting a surgical resection, prior to the intervention in the therapeutical maintenance setting) - Pregnant or lactating women - Any other malignancy within the last 5 years which has impact on the prognosis of the patient - < 4 cycles of chemotherapy in total - Contraindications to endocrine therapy - Inability or unwillingness to swallow tablets - Patients with a known intolerance to galactose, lactase deficiency and glucose-galactose malabsorption

Study Design


Intervention

Drug:
Letrozole 2.5mg
Aromatase inhibitor
Other:
Placebo
Placebo tablet of Femara

Locations

Country Name City State
Austria Krankenhaus der Barmherzigen Brüder Graz Graz
Austria Medizinische Universität Graz Graz
Austria Medizinische Universität Innsbruck Innsbruck
Austria Landeskrankenhaus Hochsteiermark Leoben Leoben
Austria Ordensklinikum Linz Barmherzige Schwestern Linz
Austria Universitätsklinikum Salzburg Salzburg
Austria Klinik Hietzing Wien Wien
Austria Medizinische Universität Wien Wien
Germany Charité - Universitätsmedizin Berlin Campus Virchow Klinikum Berlin
Germany Donauisar Klinikum Deggendorf
Germany Evangelisches Krankenhaus Düsseldorf Düsseldorf
Germany Evangelische Kliniken Essen Mitte GmbH Essen
Germany Klinikum Esslingen Esslingen
Germany University Hospital Freiburg Freiburg
Germany Gynäkologisch-Onkologische Gemeinschaftspraxis Dres. med. C.Uleer/J.Y.Pourfard Hildesheim
Germany St. Elisabeth-Krankenhaus Köln
Germany Klinikum Konstanz Konstanz
Germany University Hospital Münster Münster
Germany Studienzentrum Onkologie Ravensburg Ravensburg
Germany Leopoldina Krankenhaus der Stadt Schweinfurt Schweinfurt
Germany Helios Dr. Horst Schmidt Kliniken Wiesbaden Wiesbaden
Germany AMO Wolfsburg / AMO MVZ GmbH Wolfsburg
Switzerland Kantonsspital Aarau AG Aarau Kanton Aargau
Switzerland Kantonsspital Baden AG Baden
Switzerland Basel Claraspital AG Basel
Switzerland Universitätsspital Basel Basel Basel Stadt
Switzerland Oncology Institute of Southern Switzerland (IOSI)-Ente Ospedaliero Cantonale (EOC) Bellinzona Ticino
Switzerland Praxis im Frauenzentrum Lindenhofspital Bern
Switzerland Universitätsklinik für Medizinische Onkologie, Inselspital Bern
Switzerland Kantonspital Graubünden (KSGR), Chur
Switzerland Kantonsspital Frauenfeld Frauenfeld
Switzerland Hôpitaux Universitaires de Genève Geneva
Switzerland Frauenklinik Spital Grabs Grabs
Switzerland Universitätsspital Waadt/ CHUV Lausanne
Switzerland Kantonsspital Baselland Liestal
Switzerland Luzerner Kantonsspital Luzern
Switzerland Tumorzentrum Hirslanden Klinik St. Anna Luzern
Switzerland Kantonsspital Münsterlingen Münsterlingen
Switzerland Kantonsspital St. Gallen Saint Gallen
Switzerland Kantonsspital Winterthur Winterthur
Switzerland Klinik für Onkologie und Hämatologie Hirslanden Zürich AG Zürich
Switzerland Stadtspital Triemli Zürich
Switzerland Unispital Zürich Zürich

Sponsors (10)

Lead Sponsor Collaborator
Swiss GO Trial Group AGO Study Group, Anticancer Fund, Belgium, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Helsana AG, Hoffmann-La Roche, Krebsliga Schweiz, Novartis Pharmaceuticals, Reliable Cancer Therapies, Stiftung Guido Feger

Countries where clinical trial is conducted

Austria,  Germany,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival (PFS) for each study group PFS defined as the time from the date of first IMP administration until the date of progression (recurrence) or death by any cause in the absence of progression.
Assessment of progression (recurrence) is generally indicated by SYMPTOMS and will be assessed by the investigator most commonly on the basis of CT scans of the pelvis, abdomen and thorax, according to RECIST v1.1 criteria recommended and mostly presented by an elevated CA-125 level. Elevated CA-125 levels alone shouldn't be considered as progression. Progression assessment according to local standard of care, however, is similarly acceptable.
Up to approximately 12 years
Secondary Overall survival (OS) for each study group OS defined for each patient as the time from the date of first IMP administration until the date of death from any cause. Patients not having an event at the time of analysis will be censored at the date they were last known to be alive. Up to approximately 12 years
Secondary Quality-adjusted progression free survival (QAPFS) for each study group QAPFS defined as the time from the date of first IMP administration until the date of progression (recurrence) or death by any cause in the absence of progression under consideration of the quality of life during this period. QAPFS incorporates progression-free survival (quantity) and quality of life during this period into a measure of net clinical benefit:
QAPFS = PFS (years or months) x QoL (utility value).
Utility values derived from the EQ-5D-L5 questionnaire will be used.
Up to approximately 12 years
Secondary Time to first subsequent treatment (TFST) for each study group TFST defined for each patient as the time from the date of first IMP administration until the date the patient started the next (second-line) subsequent anticancer treatment. Patients not receiving a subsequent anticancer treatment at the time of analysis will be censored at the date they were last known to be alive. Up to approximately 12 years
Secondary Quality-adjusted time without symptoms of toxicity (Q-TWiST) for each study group Q-TWiST defined as the Quality adjusted Time Without appearance of any Symptoms of Toxicity related to either the progression of the cancer or side effects of the trial medication from the date of first IMP administration until dead.
The Q-TWiST analysis considers the following three health states:
(1) the period experiencing toxicity (TOX)
(2) the period before progression without experiencing toxicity (TWiST)
(3) the period after relapse (REL)
These periods are assigned preference utilities (u), which will be derived using the generic EQ-5D-5L questionnaire.
The Q-TWiST will be calculated as the weighted sum of the time spent in each health state:
Q-TWiST = uTox*TOX + TWiST + uRel*REL where u denotes the assigned utility for each respective health state.
Up to approximately 12 years
Secondary Health related quality of life (QoL) assessed byFunctional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES) questionnaire for each study group Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES) is included into the study to more specifically assess the side effects from the IMPs on quality of life. The minimum value is 0, the maximum value for the specific 19 item Endocrine Symptom Subscale (ESS-19) is 76. The higher the score, the better the QOL Up to approximately 5.25 years
Secondary Health related quality of life (QoL) assessed by Functional Assessment of Cancer Therapy - Ovarian (FACT-O) questionnaire for each study group In the context of this study the specific ovarian cancer symptom-oriented questionnaire Functional Assessment of Cancer Therapy - Ovarian (FACT-O) is included to assess the progression/recurrence of ovarian cancer on Quality of Life. The minimum value is 0, the maximum value including the specific Ovarian Cancer Subscale (OCS) is 152. The higher the score, the better the QOL Up to approximately 5.25 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06351475 - Efficacy of Intraoperative Use of 20% Albumin Combined With Ringer Lactate Versus Ringer Lactate During Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy N/A
Completed NCT00332696 - Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis Phase 2
Completed NCT00063401 - Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer Phase 2
Completed NCT00216372 - Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis Phase 3
Completed NCT00035100 - EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer Phase 2
Completed NCT00317772 - Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer Phase 1/Phase 2
Completed NCT00382811 - OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer Phase 3
Completed NCT00074867 - Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer Phase 2
Completed NCT00191646 - An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Phase 3
Completed NCT01846611 - A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Phase 3
Recruiting NCT05185947 - Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer Phase 2
Completed NCT03246321 - PIPAC for Peritoneal Metastases of Colorectal Cancer Phase 2
Recruiting NCT05617755 - AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer Phase 1
Completed NCT01478685 - A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT02903771 - Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. Phase 1
Completed NCT01462890 - Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer Phase 3
Withdrawn NCT01225757 - Comparison of Traditional and Echocardiography Guided Fluid Management During Cytoreductive Surgery With HIPEC N/A
Completed NCT00262990 - Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer Phase 3
Completed NCT00183794 - Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma Phase 2
Completed NCT01015118 - LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer Phase 3